iBio (IBIO) – Investment Analysts’ Recent Ratings Updates

iBio (NASDAQ: IBIO) has recently received a number of price target changes and ratings updates:

• 4/4/2026 – iBio was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/27/2026 – iBio had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 3/21/2026 – iBio was downgraded by Wall Street Zen from “hold” to “sell”.
• 3/18/2026 – iBio had its “buy” rating reaffirmed by Chardan Capital. They now have a $5.00 price target on the stock.
• 3/3/2026 – iBio is now covered by JonesTrading. They set a “buy” rating and a $7.00 price target on the stock.
• 3/2/2026 – iBio was upgraded by JonesTrading to “strong-buy”.
• 2/28/2026 – iBio was upgraded by Wall Street Zen from “sell” to “hold”.
• 2/14/2026 – iBio was downgraded by Wall Street Zen from “hold” to “sell”.
• 2/12/2026 – iBio had its “buy” rating reaffirmed by Chardan Capital. They now have a $5.00 price target on the stock.

Insider Transactions at iBio

In other iBio news, CFO Felipe Duran bought 24,835 shares of the company’s stock in a transaction on Thursday, March 19th. The shares were bought at an average cost of $2.02 per share, for a total transaction of $50,166.70. Following the acquisition, the chief financial officer directly owned 35,974 shares in the company, valued at approximately $72,667.48. The trade was a 222.96% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.75% of the stock is currently owned by insiders.

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.